Evidence map›Paper›PMID 32650630›Full record

ArticleInternational journal of molecular sciences2020

Phosphorylation of the Chaperone-Like HspB5 Rescues Trafficking and Function of F508del-CFTR.

Fanny Degrugillier, Abdel Aissat, Virginie Prulière-Escabasse, Lucie Bizard, Benjamin Simonneau, Xavier Decrouy, Chong Jiang, Daniela Rotin, Pascale Fanen, Stéphanie Simon

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Targeting ubiquitination machinery in cystic fibrosis: Where do we stand?Cellular and molecular life sciences : CMLS · 2024
    Review
  2. Review
  3. Article
  4. Review
  5. Editorial: Special Issue on "Therapeutic Approaches for Cystic Fibrosis".International journal of molecular sciences · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Fanny DegrugillierUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Abdel AissatUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Virginie Prulière-EscabasseUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.ORCID 0000-0003-0208-7544
Lucie BizardUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Benjamin SimonneauUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Xavier DecrouyUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Chong JiangThe Hospital for Sick Children and the University of Toronto, Toronto, ON M5G 0A4, Canada.
Daniela RotinThe Hospital for Sick Children and the University of Toronto, Toronto, ON M5G 0A4, Canada.ORCID 0000-0001-5201-6280
Pascale FanenUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Stéphanie SimonUniv Paris Est Creteil, INSERM, IMRB, F-94010 Creteil, France.
Inserm · FRUniversity of Toronto · CA

Funding

Association Mucoviscidose ABCF 2 naAssociation Vaincre la Mucoviscidose naCystic Fibrosis Canada naEtablissement public - Chancellerie des universités de Paris naIMRB fellowship for 'Translational Research' naInstitut National de la Santé et de la Recherche Médicale na
6 · The paper itself

Abstract

Cystic Fibrosis is a lethal monogenic autosomal recessive disease linked to mutations in Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. The most frequent mutation is the deletion of phenylalanine at position 508 of the protein. This F508del-CFTR mutation leads to misfolded protein that is detected by the quality control machinery within the endoplasmic reticulum and targeted for destruction by the proteasome. Modulating quality control proteins as molecular chaperones is a promising strategy for attenuating the degradation and stabilizing the mutant CFTR at the plasma membrane. Among the molecular chaperones, the small heat shock protein HspB1 and HspB4 were shown to promote degradation of F508del-CFTR. Here, we investigated the impact of HspB5 expression and phosphorylation on transport to the plasma membrane, function and stability of F508del-CFTR. We show that a phosphomimetic form of HspB5 increases the transport to the plasma membrane, function and stability of F508del-CFTR. These activities are further enhanced in presence of therapeutic drugs currently used for the treatment of cystic fibrosis (VX-770/Ivacaftor, VX-770+VX-809/Orkambi). Overall, this study highlights the beneficial effects of a phosphorylated form of HspB5 on F508del-CFTR rescue and its therapeutic potential in cystic fibrosis.

Indexed as

AminophenolsAminopyridinesAnimalsBenzodioxolesCell LineCell MembraneCrystallinsCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsHeat-Shock ProteinsHEK293 CellsHumansMaleMiceMolecular ChaperonesAminophenolsAminopyridinesBenzodioxolesCFTR protein, humanCrystallinsCystic Fibrosis Transmembrane Conductance RegulatorDrug CombinationsHeat-Shock Proteinsivacaftorlumacaftorlumacaftor, ivacaftor drug combinationMolecular ChaperonesPhenylalanineProteasome Endopeptidase ComplexQuinolonesalpha B-crystallinCFTRCRYABcystic fibrosisHspB5phosphorylation

Identifiers

PMID32650630
PMCPMC7402320
OpenAlexW3041839529

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.